Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 71
Filter
2.
Endocr Relat Cancer ; 11(4): 725-48, 2004 Dec.
Article in English | MEDLINE | ID: mdl-15613448

ABSTRACT

Gonadotropin-releasing hormone (GnRH) is the hypothalamic factor that mediates reproductive competence. Intermittent GnRH secretion from the hypothalamus acts upon its receptor in the anterior pituitary to regulate the production and release of the gonadotropins, LH and FSH. LH and FSH then stimulate sex steroid hormone synthesis and gametogenesis in the gonads to ensure reproductive competence. The pituitary requires pulsatile stimulation by GnRH to synthesize and release the gonadotropins LH and FSH. Clinically, native GnRH is used in a pump delivery system to create an episodic delivery pattern to restore hormonal defects in patients with hypogonadotropic hypogonadism. Agonists of GnRH are delivered in a continuous mode to turn off reproductive function by inhibiting gonadotropin production, thus lowering sex steroid production, resulting in medical castration. They have been used in endocrine disorders such as precocious puberty, endometriosis and leiomyomata, but are also studied extensively in hormone-dependent malignancies. The detection of GnRH and its receptor in other tissues, including the breast, ovary, endometrium, placenta and prostate suggested that GnRH agonists and antagonists may also have direct actions at peripheral targets. This paper reviews the current data concerning differential control of GnRH and GnRH receptor expression and signaling in the hypothalamic-pituitary axis and extrapituitary tissues. Using these data as a backdrop, we then review the literature about the action of GnRH in cancer cells, the utility of GnRH analogs in various malignancies and then update the research in novel therapies targeted to the GnRH receptor in cancer cells to promote anti-proliferative effects and control of tumor burden.


Subject(s)
Gonadotropin-Releasing Hormone/metabolism , Neoplasms, Hormone-Dependent/metabolism , Receptors, LHRH/metabolism , Animals , Cell Line, Tumor , Cell Proliferation , Female , Gonadotropin-Releasing Hormone/agonists , Gonadotropin-Releasing Hormone/analogs & derivatives , Gonadotropin-Releasing Hormone/antagonists & inhibitors , Humans , Hypothalamus/metabolism , Male , Neoplasms, Hormone-Dependent/drug therapy , Pituitary Gland, Anterior/metabolism , Signal Transduction
3.
Hematol Oncol Clin North Am ; 15(3): 583-92, 2001 Jun.
Article in English | MEDLINE | ID: mdl-11525299

ABSTRACT

Whether the benefits will outweigh the risks of electronic health care remains to be seen, and to a large extent the question is moot; consumers, providers, and interested third parties have ensured its existence. One can surmise, or at least hope, that all interested parties will become increasingly sophisticated in both the delivery and consumption of e-health information, and that ultimately consumer, advocate, and physician demands will help shape the industry into a self-regulated entity that balances the need for high-grade information with a commitment to the principles of privacy and autonomy.


Subject(s)
Internet , Medical Oncology , Patients/psychology , Computer Literacy , Computer Security , Confidentiality , Humans , Information Services , Male , Medical Records , Patient Education as Topic , Physician-Patient Relations , Quackery , Risk , Self Care , Self-Help Groups
4.
Rev Urol ; 3 Suppl 2: S2-S10, 2001.
Article in English | MEDLINE | ID: mdl-16985996

ABSTRACT

Recent advances in the understanding of prostate cancer pathology, screening methods, and epidemiology were discussed at the 11th International Prostate Cancer Update. Regarding pathology, Dr. Gary Miller enumerated several factors that lead to the perception of prostate cancer as "unpredictable." These include the disease's multifocal nature, variable progression rates, and the uncertainty regarding the point at which carcinomas metastasize. Screening methods have been the subject of research by the Laval University Prostate Cancer Screening Program since 1988. Dr. Fernand Labrie presented the results of this 10-year study. Dr. Daisaku Hirano presented data from his studies of prostate cancer epidemiology in Japan as compared to the United States. The role of environmental factors, particularly diet, in prostate cancer pathogenesis and development is supported by the increase of the disease in Japan, concurrent with the "westernization" of diet there. Finally, useful information was presented on new computer- and Internet-based diagnostic and research tools.

5.
Rev Urol ; 3 Suppl 2: S69-78, 2001.
Article in English | MEDLINE | ID: mdl-16986001

ABSTRACT

Several presentations by attendees of the 11th International Prostate Cancer Update addressed recent advances in prostate cancer treatment. A study that examined whether a relationship exists between neuroendocrine (NE) cell differentiation and hormone-refractory prostate cancer (HRPC) concluded that the appearance of NE cells in prostatic carcinoma is an important phenomenon in the development of HRPC. Exisuland, a selective apoptotic antineoplastic drug, was compared to placebo in a recent study and was found to significantly inhibit the increase of prostate-specific antigen in patients who had undergone radical prostatectomy. A new dosing regimen for flutamide (500 mg daily) was found to have no significant differences from the currently recommended dose (250 mg every 8 hours); the new, single daily dose could meet with greater compliance and would reduce drug cost by 30%. The antiproliferative effect of vitamin D on prostatic carcinoma cells was discussed, along with the possible role of vitamin D supplementation during prostate cancer treatment. Finally, a presentation on hospice care acknowledged that referral for such care is unfortunately at times delayed by physicians, patients, and patients' families, leaving insufficient time for all the benefits of that stage of care to be realized.

6.
Mol Cell Probes ; 14(4): 211-7, 2000 Aug.
Article in English | MEDLINE | ID: mdl-10970725

ABSTRACT

New diagnostic tools are needed for the early detection of prostatic cancer. The molecular detection of prostate cancer cells in ejaculates was evaluated using complementary PCR-based methods. LNCaP cells, a cell line derived from prostatic carcinoma, were spiked into normal seminal ejaculates and the prostatic epithelial component of the specimens was isolated by immunomagnetic bead sorting, using a monoclonal antibody to prostate-specific membrane antigen (PSMA). Ejaculates from nine patients with a recent diagnosis of prostate cancer were processed in a similar fashion, using LNCaP-spiked aliquots as an internal positive control. Telomerase expression was evaluated by the telomeric repeat amplification protocol (TRAP) and glutathione S-transferase gene promoter (GSTP1) hypermethylation was evaluated by methylation-sensitive restriction endonuclease digestion and PCR amplification. Telomerase activity was detected in LNCaP cells recovered from normal seminal ejaculates but was not found in all nine samples from patients with prostate cancer. The sensitivity of GSTP1 analysis was similar to telomerase analysis for the detection of LNCaP cells from normal ejaculate samples but was positive in ejaculates from four out of nine patients with prostate cancer. GSTP1 DNA methylation status is more sensitive than telomerase analysis for the detection of malignant cells in seminal ejaculates from patients with prostate cancer.


Subject(s)
Glutathione Transferase/genetics , Isoenzymes/genetics , Prostatic Neoplasms/diagnosis , Prostatic Neoplasms/genetics , Telomerase/metabolism , DNA Methylation , Ejaculation , Glutathione S-Transferase pi , Humans , Male , Mass Screening/methods , Promoter Regions, Genetic , Reference Values , Spermatozoa/physiology , Telomerase/analysis , Tumor Cells, Cultured
8.
Int J Mol Med ; 5(3): 241-5, 2000 Mar.
Article in English | MEDLINE | ID: mdl-10677563

ABSTRACT

Semliki Forest Virus (SFV) is a broad host range RNA virus capable of high-level recombinant protein expression and apoptosis induction in many cell types. We have successfully used a recombinant, replication deficient SFV vector to express the LacZ marker gene product in seven human prostate cell lines, as well as in human prostate tissue explants. Flow cytometry revealed that 40-60% of PPC-1 prostate cancer cells died 24-72 h after infection with SFV-LacZ virus. Most human prostate cancer cell lines expressed high levels of recombinant protein. Infection of human prostate tissue ex vivo led to similarly high expression levels but the recombinant beta-galactosidase was confined to duct epithelial cells. Infection of cell and tissue cultures resulted in detachment of adherent cells from the culture surface and detachment of epithelial cells from the basement membrane of tissue. Our results indicate that SFV may be useful in targeting recombinant protein expression and apoptosis to prostatic duct epithelial cells.


Subject(s)
Apoptosis , Genetic Vectors/physiology , Prostate/cytology , Prostatic Neoplasms/pathology , Semliki forest virus/physiology , Cells, Cultured , Epithelial Cells/cytology , Epithelial Cells/virology , Gene Expression , Genetic Vectors/genetics , Humans , Lac Operon , Male , Prostate/virology , Prostatic Neoplasms/virology , Recombination, Genetic , Semliki forest virus/genetics , Tumor Cells, Cultured
10.
Prostate Cancer Prostatic Dis ; 2(S1): 19-20, 1999 Jan.
Article in English | MEDLINE | ID: mdl-12496852

ABSTRACT

Understanding the role of chemotherapy for prostate cancer has advanced along two axes, better definition of endpoints, and biologic understanding of disease targets. Use of PSA as a surrogate endpoint makes possible the more rational design of phase III trials which will include survival and disease free intervals as an endpoint. Pain control has emerged as an important treatment endpoint through which more cost-effective care can be envisioned. Discovery of growth factor interactions with prostate cancer cells and the elucidation of apoptotic pathways have provided numerous new targets for biologic and chemotherapy of advanced disease.

12.
Am J Obstet Gynecol ; 177(3): 579-85, 1997 Sep.
Article in English | MEDLINE | ID: mdl-9322627

ABSTRACT

OBJECTIVE: Our goal was to determine whether toxicity of the diphtheria toxin A-chain gene regulated by the human chorionic gonadotropin promoter can be directed to malignant ovarian cell lines. STUDY DESIGN: Plasmids containing diphtheria toxin A-chain gene linked to the regulatory elements of the metalloergothioneine and human chorionic gonadotropin promoters were transfected into the cell lines. Expression of diphtheria toxin A-chain gene was determined by the inhibition of a cotransfected luciferase reporter gene. RESULTS: Cytotoxicity of the diphtheria toxin A-chain gene is shown in a dose-responsive manner. Transfection of a plasmid expressing the diphtheria toxin A-chain gene controlled by a constitutive promoter readily inhibits protein synthesis. Specific inhibition of luciferase protein synthesis occurs in ovarian cancer cells transfected with the diphtheria toxin A-chain gene under the control of the human chorionic gonadotropin promoters when compared with normal ovarian epithelial cells or fibroblasts. CONCLUSIONS: These data demonstrate the preferential expression of the diphtheria toxin A-chain gene, regulated by the human chorionic gonadotropin promoter, to ovarian cancer cell lines. This provides an avenue for targeting such cells for suicide, toxin, or cytokine genes.


Subject(s)
Carcinoma/pathology , Chorionic Gonadotropin/genetics , Diphtheria Toxin/genetics , Ovarian Neoplasms/pathology , Promoter Regions, Genetic/physiology , Carcinoma/chemistry , Carcinoma/metabolism , Chorionic Gonadotropin/analysis , Chorionic Gonadotropin/physiology , Chorionic Gonadotropin, beta Subunit, Human/analysis , Chorionic Gonadotropin, beta Subunit, Human/metabolism , Diphtheria Toxin/physiology , Diphtheria Toxin/toxicity , Dose-Response Relationship, Drug , Epithelial Cells/cytology , Epithelium/chemistry , Epithelium/metabolism , Female , Gene Expression Regulation, Enzymologic , Gene Expression Regulation, Neoplastic/drug effects , Humans , Luciferases/analysis , Luciferases/genetics , Ovarian Neoplasms/chemistry , Ovarian Neoplasms/metabolism , Ovary/chemistry , Ovary/cytology , Ovary/metabolism , Peptide Fragments/analysis , Peptide Fragments/metabolism , Plasmids , Promoter Regions, Genetic/genetics , Transfection , Tumor Cells, Cultured
13.
Oncology (Williston Park) ; 11(6): 845-50, 856; discussion 856-8, 861, 1997 Jun.
Article in English | MEDLINE | ID: mdl-9189941

ABSTRACT

Gene therapy for prostate cancer faces hurdles similar to those being encountered for other cancers and nonmalignant processes. The greatest obstacle is the identification of efficient delivery systems, since numerous animal models and cell culture systems have shown potential efficacy when most cells express the introduced genetic material. Early prostate cancers are easily accessible to gene vector introduction, and the predictable metastatic patterns of this cancer may offer additional advantages for gene therapy. This article reviews gene vectors and gene products, as well as ongoing trials of gene therapy that have recently begun in prostate cancer.


Subject(s)
Genetic Therapy , Prostatic Neoplasms/therapy , Animals , Drug Delivery Systems , Gene Transfer Techniques , Genetic Therapy/methods , Genetic Therapy/trends , Genetic Vectors/administration & dosage , Genetic Vectors/therapeutic use , Humans , Male , Safety , Treatment Outcome , Viruses/genetics
14.
J Clin Oncol ; 14(7): 2181-6, 1996 Jul.
Article in English | MEDLINE | ID: mdl-8683253

ABSTRACT

PURPOSE: The internet, and in particular the world wide web (www), has a rapidly increasing potential to provide information for oncologists and their patients about cancer biology and treatment. A brief overview of this environment is given along with examples of how easily the information is accessed as a means of introducing the web page of the American Society of Clinical Oncology (ASCO), ASCO OnLine. METHODS: Oncology information sources on the www were accessed from the author's home using a 14.4 kbs modem, Netscape browser (Netscape communications Corp, Mountain View, CA), and the locations recorded for tabulation and discussion. RESULTS: Overwhelming amounts of oncology-related information are now available via the Internet. CONCLUSION: Oncology as a subspecialty is ideally suited to apply the newest information technology to traditional needs in areas of education, research, and patient care. Oncologists will increasingly act as information guides rather than information resources for patients and their families with cancer.


Subject(s)
Computer Communication Networks , Medical Oncology , Humans , Information Services
15.
J Natl Cancer Inst ; 87(11): 809-16, 1995 Jun 07.
Article in English | MEDLINE | ID: mdl-7791230

ABSTRACT

BACKGROUND: At present, there is no highly effective treatment for metastatic melanoma. Innovative approaches aimed at inducing a more effective immune response against tumors have shown promising results in animal models. One approach involves the genetic modification of tumor cells so that they produce cytokines that stimulate an immune response. PURPOSE: The aim of this study was to determine the effectiveness of cytokine gene therapy for metastatic melanoma in a murine melanoma model. METHODS: B16F10 murine melanoma cells, which readily metastasize to the lungs, were transduced with a retroviral vector containing genes encoding neomycin resistance and human macrophage colony-stimulating factor (M-CSF). The presence of M-CSF messenger RNA in transduced cells was examined by coupled reverse transcription and polymerase chain reaction. Concentrations of soluble M-CSF in cell culture supernatants were determined by enzyme-linked immunosorbent assays (ELISAs). A clonal cell line, designated N+/CSF+, that expressed and secreted M-CSF was identified. Another clonal cell line, designated N+/CSF-, did not secrete M-CSF at levels detectable by ELISA. B16F10, N+/CSF-, and N+/CSF+ cells, individually or in combination, were injected intravenously or subcutaneously into C57BL/6 mice; we then evaluated the tumorigenicity and metastatic behavior of the cells, as well as the immune responses and survival of the mice. The immune responses assayed were the cytotoxic T lymphocyte (CTL) and peritoneal exudate cell (PEC) tumoricidal activities. RESULTS: Injection of B16F10 cells into the tail vein of C57BL/6 mice led to the establishment of lung metastases by week 2 and death by week 8. Injection of the N+/CSF+ or N+/CSF- cells led to the establishment of lung metastases that were detected at 2 and 3 weeks, respectively; however, these metastatic lesions were eliminated, and the animals had survival rates similar to those of the noninjected control mice. Injection of mice with a mixture of B16F10 and N+/CSF- cells resulted in the development of metastatic disease and 0% survival at 8 weeks, whereas mice that had been given an injection of a mixture of B16F10 and N+/CSF+ cells had an 80% survival rate at 8 weeks and survived at least two times longer (P = .007). The CTL and PEC tumoricidal activities in animals given an injection of N+/CSF+ cells suggested that monocytes and lymphocytes were responsible for the observed antitumor response. CONCLUSION: These findings suggest that the expression of M-CSF by genetically modified melanoma cells caused an effective antitumor immune response in host C57BL/6 mice and, thus, prolonged survival over that observed in the control mice.


Subject(s)
Genetic Therapy/methods , Lung Neoplasms/therapy , Macrophage Colony-Stimulating Factor/genetics , Melanoma/therapy , Animals , Base Sequence , Enzyme-Linked Immunosorbent Assay , Exudates and Transudates/cytology , Lung Neoplasms/immunology , Lung Neoplasms/secondary , Melanoma/immunology , Melanoma/secondary , Mice , Mice, Inbred C57BL , Molecular Sequence Data , Peritoneum , Polymerase Chain Reaction , T-Lymphocytes , Transcription, Genetic , Tumor Cells, Cultured
17.
Cancer Biother ; 9(2): 131-41, 1994.
Article in English | MEDLINE | ID: mdl-7812362

ABSTRACT

Despite advances in conventional therapy, many lives continue to be lost to common forms of B-cell cancers, including leukemias, lymphomas and multiple myeloma. We propose a novel approach to therapy of such cancers using controlled expression of a diphtheria toxin gene (DT-A) to kill malignant cells. We have previously demonstrated selective killing of various cell types, in vitro and in vivo, by cell-specific, transcriptionally controlled expression of this gene. Organ-specific ablation in otherwise healthy transgenic mice has convincingly demonstrated the exquisite specificity achievable by this technique. In the studies now described, DT-A was delivered in vitro and in vivo using a novel gene delivery system employing DNA physically attached to the exterior of adenovirus. After demonstrating the efficacy of gene delivery to Epstein-Barr virus transformed human B-cells in vitro, in vivo work was performed using a SCID mouse model for B-cell lymphoma, in which protection against tumor was observed. The concepts of tissue-regulated toxin gene therapy, and this novel adenovirus gene delivery system are discussed.


Subject(s)
Adenoviridae , DNA, Recombinant/administration & dosage , Diphtheria Toxin/therapeutic use , Genes, Immunoglobulin , Genes, Synthetic , Genetic Therapy , Immunoglobulin kappa-Chains/genetics , Lymphoma, B-Cell/therapy , Peptide Fragments/therapeutic use , Polylysine , Promoter Regions, Genetic , Animals , Biotin , Cell Line, Transformed , Diphtheria Toxin/biosynthesis , Diphtheria Toxin/genetics , Female , Gene Expression Regulation, Neoplastic , Genes, Reporter , Herpesvirus 4, Human , Ligands , Lymphoma, B-Cell/genetics , Lymphoma, B-Cell/immunology , Male , Mice , Mice, SCID , Peptide Fragments/biosynthesis , Peptide Fragments/genetics , Recombinant Fusion Proteins/biosynthesis , Recombinant Fusion Proteins/genetics , Recombinant Fusion Proteins/therapeutic use
18.
Leuk Lymphoma ; 7(5-6): 457-62, 1992 Aug.
Article in English | MEDLINE | ID: mdl-1493446

ABSTRACT

Specifically targeted expression of a toxin gene potentially represents a novel approach to cancer therapy. With a view to the ablation of B-cell malignancies, we have constructed a plasmid, designated pTHA71, which expresses the A-chain of diphtheria toxin (DT-A) with high efficiency and specificity in transfected, mature B-lymphoid cells. The construction incorporated immunoglobulin (Ig) kappa light chain gene regulatory sequences, including a kappa promoter, small intron, partial constant region exon, and 3'-flanking sequence (but lacking a known enhancer). These sequences conferred substantially more efficient expression of DT-A in mature B-cells than was seen from constructs that included only Ig promoters and enhancers. When transfected into the 70Z/3 murine pre-B-cell line, pTHA71 was only expressed efficiently if the cells were induced to express their endogenous, rearranged Ig kappa gene by prior exposure to lipopolysaccharide. The insertion of the enhancer from the Ig kappa large intron into pTHA71, generating pTHA81, did not markedly influence the level of DT-A expression in 70Z/3 cells. The observed absence of expression in pre-B-cells suggests that DT-A constructs similar to pTHA71 might be used for the therapeutic ablation of malignant B-cells of mature stages, while sparing normal progenitor cells.


Subject(s)
B-Lymphocytes/metabolism , Diphtheria Toxin/genetics , Genes, Immunoglobulin , Genetic Therapy , Immunoglobulin kappa-Chains/genetics , Lymphoma, B-Cell/therapy , Peptide Fragments/genetics , Animals , Mice , Plasmids , Transfection
19.
Prostate ; 20(2): 123-31, 1992.
Article in English | MEDLINE | ID: mdl-1549551

ABSTRACT

The unavailability of effective treatment of metastatic hormone refractory prostatic carcinoma warrants trials of new and promising treatments. Coumarin is an investigational new drug that has produced objective tumor regression in some patients with metastatic renal cell carcinoma and malignant melanoma. Coumarin has shown activity against prostatic carcinoma in the Dunning R-3327 rat prostatic adenocarcinoma model. Forty-eight patients with metastatic hormone naive (5 stage D1 and 10 stage D2) or hormone refractory (33 stage D3) prostatic carcinoma of average age 67.6 years (range 46-86) and ECOG performance status of 2 or better were given 3 grams coumarin daily by mouth and evaluated monthly for toxicity and response by rigid criteria in a multicenter trial. Toxicity was limited to asymptomatic SGOT elevations in 3 patients and nausea and vomiting in 4 patients that required cessation of therapy in 2. Eligibility and protocol violations removed 6 additional patients from response evaluation. There were no complete responses. Partial responses (3 of 40 patients, 8%) occurred in 2 patients with bidimentionally measurable disease and 1 patient with disease evaluable by bone scan and elevated prostate specific antigen and prostatic acid phosphatase. The remaining patients progressed after 1 to 12 (average 4.4) months. Coumarin is a relatively nontoxic drug that may warrant further trials in a subset of patients with prostatic carcinoma.


Subject(s)
Carcinoma/drug therapy , Coumarins/therapeutic use , Prostatic Neoplasms/drug therapy , Adult , Aged , Drug Evaluation , Humans , Male , Neoplasm Metastasis
20.
AIDS Res Hum Retroviruses ; 8(1): 39-45, 1992 Jan.
Article in English | MEDLINE | ID: mdl-1736939

ABSTRACT

Construction of a DNA plasmid that expresses a diphtheria toxin A chain (DT-A) gene under control of human immunodeficiency virus (HIV-1) proteins Tat and Rev has been described. Here the generation of HeLa cell clones containing integrated, HIV-regulated DT-A sequences is reported. Five such clones were identified by their decreased expression of a luciferase reporter gene transiently cotransfected with Tat- and Rev-encoding plasmids. The decreased luciferase expression most probably was due to activation of the integrated DT-A gene because higher luciferase activity could be restored by introducing either DT antitoxin or a gene encoding a mutant, DT-resistant elongation factor 2 (the intracellular target for DT-A). Analysis by polymerase chain reaction (PCR) indicated that all clones expressed DT-A encoding RNA. The clones were then transfected with an HIV proviral clone and were tested for HIV production; all five clones demonstrated substantially impaired HIV production compared with parental HeLa cells, as shown by p24 assays of culture supernatants. Our success in generating these cell lines indicates that extremely low basal expression has been achieved in view of the high cellular lethality of DT-A. HIV-regulated expression of DT-A may be applicable as a gene therapy approach for the acquired immune deficiency syndrome (AIDS), to bring about selective suicide of HIV-infected cells before production of viral progeny.


Subject(s)
Diphtheria Toxin/genetics , Gene Expression Regulation, Viral , Genes, Viral , HIV-1/physiology , Peptide Fragments/genetics , Virus Replication/genetics , Cloning, Molecular , DNA, Viral/chemistry , HIV-1/genetics , HIV-1/immunology , HeLa Cells , Humans , Plasmids , Polymerase Chain Reaction , Proviruses/genetics , Transfection
SELECTION OF CITATIONS
SEARCH DETAIL
...